Loading…

Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and its incidence continues to increase each year. Yet, there is still no definitive drug that can stop its development. This review focuses mainly on lipotoxicity, oxidative stress, inflammation, and in...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2023-07, Vol.28 (15), p.5645
Main Authors: Fang, Xiaolei, Song, Jiayu, Zhou, Kaixuan, Zi, Xue, Sun, Bin, Bao, Huiwei, Li, Lijing
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c561t-6c1cbbb61004e2880754528984752c8666ddeb5f4a35f77a23e2699a319689003
cites cdi_FETCH-LOGICAL-c561t-6c1cbbb61004e2880754528984752c8666ddeb5f4a35f77a23e2699a319689003
container_end_page
container_issue 15
container_start_page 5645
container_title Molecules (Basel, Switzerland)
container_volume 28
creator Fang, Xiaolei
Song, Jiayu
Zhou, Kaixuan
Zi, Xue
Sun, Bin
Bao, Huiwei
Li, Lijing
description Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and its incidence continues to increase each year. Yet, there is still no definitive drug that can stop its development. This review focuses mainly on lipotoxicity, oxidative stress, inflammation, and intestinal flora dysbiosis to understand NAFLD's pathogenesis. In this review, we used NCBI's PubMed database for retrieval, integrating in vivo and in vitro experiments to reveal the therapeutic effects of natural compounds on NAFLD. We also reviewed the mechanisms by which the results of these experiments suggest that these compounds can protect the liver from damage by modulating inflammation, reducing oxidative stress, decreasing insulin resistance and lipid accumulation in the liver, and interacting with the intestinal microflora. The natural compounds discussed in these papers target a variety of pathways, such as the AMPK pathway and the TGF-β pathway, and have significant therapeutic effects. This review aims to provide new possible therapeutic lead compounds and references for the development of novel medications and the clinical treatment of NAFLD. It offers fresh perspectives on the development of natural compounds in preventing and treating NAFLD.
doi_str_mv 10.3390/molecules28155645
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b7a4f73c71bf4f4abe23928ca08a2b65</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A760516853</galeid><doaj_id>oai_doaj_org_article_b7a4f73c71bf4f4abe23928ca08a2b65</doaj_id><sourcerecordid>A760516853</sourcerecordid><originalsourceid>FETCH-LOGICAL-c561t-6c1cbbb61004e2880754528984752c8666ddeb5f4a35f77a23e2699a319689003</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEoqXwA7igSFy4pPj744RWWwqVtsChnC3HmWy8SuLFTor23-PtltIF5IOt8fs-4xlPUbzG6JxSjd4PoQc395CIwpwLxp8Up5gRVFHE9NNH55PiRUobhAhmmD8vTqjkEgnMT4vu-sCwsbwG19nRp6H8Zqfup92lMrTlFzvN0fblMgzbMI9NKtsQy6mD8iaCnQYYpztZGKtF70IXeu_KSztNu3LlbyGWFz6BTfCyeNbaPsGr-_2s-H758Wb5uVp9_XS1XKwqxwWeKuGwq-taYIQYEKWQ5IwTpRWTnDglhGgaqHnLLOWtlJZQIEJrS7EWSiNEz4qrA7cJdmO20Q827kyw3twFQlwbGyfvejC1tKyV1ElctywTayBUE-UsUpbUgmfWhwNrO9cDNC7XmltxBD2-GX1n1uHWYMSwlnr_mnf3hBh-zJAmM_jkoO_tCGFOhiiOKFJayyx9-5d0E-Y45l5lFdP5uzLzj2ptcwV-bENO7PZQs5ACcSwUp1l1_h9VXg0M3oURWp_jRwZ8MLgYUorQPhSJkdnPmvln1rLnzePuPDh-Dxf9BRW00AM</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2849061419</pqid></control><display><type>article</type><title>Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>Coronavirus Research Database</source><creator>Fang, Xiaolei ; Song, Jiayu ; Zhou, Kaixuan ; Zi, Xue ; Sun, Bin ; Bao, Huiwei ; Li, Lijing</creator><creatorcontrib>Fang, Xiaolei ; Song, Jiayu ; Zhou, Kaixuan ; Zi, Xue ; Sun, Bin ; Bao, Huiwei ; Li, Lijing</creatorcontrib><description>Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and its incidence continues to increase each year. Yet, there is still no definitive drug that can stop its development. This review focuses mainly on lipotoxicity, oxidative stress, inflammation, and intestinal flora dysbiosis to understand NAFLD's pathogenesis. In this review, we used NCBI's PubMed database for retrieval, integrating in vivo and in vitro experiments to reveal the therapeutic effects of natural compounds on NAFLD. We also reviewed the mechanisms by which the results of these experiments suggest that these compounds can protect the liver from damage by modulating inflammation, reducing oxidative stress, decreasing insulin resistance and lipid accumulation in the liver, and interacting with the intestinal microflora. The natural compounds discussed in these papers target a variety of pathways, such as the AMPK pathway and the TGF-β pathway, and have significant therapeutic effects. This review aims to provide new possible therapeutic lead compounds and references for the development of novel medications and the clinical treatment of NAFLD. It offers fresh perspectives on the development of natural compounds in preventing and treating NAFLD.</description><identifier>ISSN: 1420-3049</identifier><identifier>EISSN: 1420-3049</identifier><identifier>DOI: 10.3390/molecules28155645</identifier><identifier>PMID: 37570615</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antioxidants ; Care and treatment ; Cytokines ; Enzymes ; Fatty acids ; Fatty liver ; Flavonoids ; Health aspects ; hepatic steatosis ; Homeostasis ; Humans ; Inflammation ; Inflammation - metabolism ; Insulin Resistance ; Lipids ; Liver ; Liver diseases ; Metabolism ; Metabolites ; Microbiota ; Microbiota (Symbiotic organisms) ; natural compounds ; non-alcoholic fatty liver disease ; Non-alcoholic Fatty Liver Disease - metabolism ; Oxidation ; Oxidative Stress ; Pathogenesis ; Proteins ; Review ; Sterols ; Transcription factors ; Transforming growth factors ; Tumor necrosis factor-TNF ; Type 2 diabetes</subject><ispartof>Molecules (Basel, Switzerland), 2023-07, Vol.28 (15), p.5645</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c561t-6c1cbbb61004e2880754528984752c8666ddeb5f4a35f77a23e2699a319689003</citedby><cites>FETCH-LOGICAL-c561t-6c1cbbb61004e2880754528984752c8666ddeb5f4a35f77a23e2699a319689003</cites><orcidid>0000-0001-7621-0715</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2849061419/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2849061419?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25751,27922,27923,37010,37011,38514,43893,44588,53789,53791,74182,74896</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37570615$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fang, Xiaolei</creatorcontrib><creatorcontrib>Song, Jiayu</creatorcontrib><creatorcontrib>Zhou, Kaixuan</creatorcontrib><creatorcontrib>Zi, Xue</creatorcontrib><creatorcontrib>Sun, Bin</creatorcontrib><creatorcontrib>Bao, Huiwei</creatorcontrib><creatorcontrib>Li, Lijing</creatorcontrib><title>Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease</title><title>Molecules (Basel, Switzerland)</title><addtitle>Molecules</addtitle><description>Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and its incidence continues to increase each year. Yet, there is still no definitive drug that can stop its development. This review focuses mainly on lipotoxicity, oxidative stress, inflammation, and intestinal flora dysbiosis to understand NAFLD's pathogenesis. In this review, we used NCBI's PubMed database for retrieval, integrating in vivo and in vitro experiments to reveal the therapeutic effects of natural compounds on NAFLD. We also reviewed the mechanisms by which the results of these experiments suggest that these compounds can protect the liver from damage by modulating inflammation, reducing oxidative stress, decreasing insulin resistance and lipid accumulation in the liver, and interacting with the intestinal microflora. The natural compounds discussed in these papers target a variety of pathways, such as the AMPK pathway and the TGF-β pathway, and have significant therapeutic effects. This review aims to provide new possible therapeutic lead compounds and references for the development of novel medications and the clinical treatment of NAFLD. It offers fresh perspectives on the development of natural compounds in preventing and treating NAFLD.</description><subject>Antioxidants</subject><subject>Care and treatment</subject><subject>Cytokines</subject><subject>Enzymes</subject><subject>Fatty acids</subject><subject>Fatty liver</subject><subject>Flavonoids</subject><subject>Health aspects</subject><subject>hepatic steatosis</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation - metabolism</subject><subject>Insulin Resistance</subject><subject>Lipids</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Microbiota</subject><subject>Microbiota (Symbiotic organisms)</subject><subject>natural compounds</subject><subject>non-alcoholic fatty liver disease</subject><subject>Non-alcoholic Fatty Liver Disease - metabolism</subject><subject>Oxidation</subject><subject>Oxidative Stress</subject><subject>Pathogenesis</subject><subject>Proteins</subject><subject>Review</subject><subject>Sterols</subject><subject>Transcription factors</subject><subject>Transforming growth factors</subject><subject>Tumor necrosis factor-TNF</subject><subject>Type 2 diabetes</subject><issn>1420-3049</issn><issn>1420-3049</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkk1v1DAQhiMEoqXwA7igSFy4pPj744RWWwqVtsChnC3HmWy8SuLFTor23-PtltIF5IOt8fs-4xlPUbzG6JxSjd4PoQc395CIwpwLxp8Up5gRVFHE9NNH55PiRUobhAhmmD8vTqjkEgnMT4vu-sCwsbwG19nRp6H8Zqfup92lMrTlFzvN0fblMgzbMI9NKtsQy6mD8iaCnQYYpztZGKtF70IXeu_KSztNu3LlbyGWFz6BTfCyeNbaPsGr-_2s-H758Wb5uVp9_XS1XKwqxwWeKuGwq-taYIQYEKWQ5IwTpRWTnDglhGgaqHnLLOWtlJZQIEJrS7EWSiNEz4qrA7cJdmO20Q827kyw3twFQlwbGyfvejC1tKyV1ElctywTayBUE-UsUpbUgmfWhwNrO9cDNC7XmltxBD2-GX1n1uHWYMSwlnr_mnf3hBh-zJAmM_jkoO_tCGFOhiiOKFJayyx9-5d0E-Y45l5lFdP5uzLzj2ptcwV-bENO7PZQs5ACcSwUp1l1_h9VXg0M3oURWp_jRwZ8MLgYUorQPhSJkdnPmvln1rLnzePuPDh-Dxf9BRW00AM</recordid><startdate>20230725</startdate><enddate>20230725</enddate><creator>Fang, Xiaolei</creator><creator>Song, Jiayu</creator><creator>Zhou, Kaixuan</creator><creator>Zi, Xue</creator><creator>Sun, Bin</creator><creator>Bao, Huiwei</creator><creator>Li, Lijing</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7621-0715</orcidid></search><sort><creationdate>20230725</creationdate><title>Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease</title><author>Fang, Xiaolei ; Song, Jiayu ; Zhou, Kaixuan ; Zi, Xue ; Sun, Bin ; Bao, Huiwei ; Li, Lijing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c561t-6c1cbbb61004e2880754528984752c8666ddeb5f4a35f77a23e2699a319689003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antioxidants</topic><topic>Care and treatment</topic><topic>Cytokines</topic><topic>Enzymes</topic><topic>Fatty acids</topic><topic>Fatty liver</topic><topic>Flavonoids</topic><topic>Health aspects</topic><topic>hepatic steatosis</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation - metabolism</topic><topic>Insulin Resistance</topic><topic>Lipids</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Microbiota</topic><topic>Microbiota (Symbiotic organisms)</topic><topic>natural compounds</topic><topic>non-alcoholic fatty liver disease</topic><topic>Non-alcoholic Fatty Liver Disease - metabolism</topic><topic>Oxidation</topic><topic>Oxidative Stress</topic><topic>Pathogenesis</topic><topic>Proteins</topic><topic>Review</topic><topic>Sterols</topic><topic>Transcription factors</topic><topic>Transforming growth factors</topic><topic>Tumor necrosis factor-TNF</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fang, Xiaolei</creatorcontrib><creatorcontrib>Song, Jiayu</creatorcontrib><creatorcontrib>Zhou, Kaixuan</creatorcontrib><creatorcontrib>Zi, Xue</creatorcontrib><creatorcontrib>Sun, Bin</creatorcontrib><creatorcontrib>Bao, Huiwei</creatorcontrib><creatorcontrib>Li, Lijing</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Molecules (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fang, Xiaolei</au><au>Song, Jiayu</au><au>Zhou, Kaixuan</au><au>Zi, Xue</au><au>Sun, Bin</au><au>Bao, Huiwei</au><au>Li, Lijing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease</atitle><jtitle>Molecules (Basel, Switzerland)</jtitle><addtitle>Molecules</addtitle><date>2023-07-25</date><risdate>2023</risdate><volume>28</volume><issue>15</issue><spage>5645</spage><pages>5645-</pages><issn>1420-3049</issn><eissn>1420-3049</eissn><abstract>Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and its incidence continues to increase each year. Yet, there is still no definitive drug that can stop its development. This review focuses mainly on lipotoxicity, oxidative stress, inflammation, and intestinal flora dysbiosis to understand NAFLD's pathogenesis. In this review, we used NCBI's PubMed database for retrieval, integrating in vivo and in vitro experiments to reveal the therapeutic effects of natural compounds on NAFLD. We also reviewed the mechanisms by which the results of these experiments suggest that these compounds can protect the liver from damage by modulating inflammation, reducing oxidative stress, decreasing insulin resistance and lipid accumulation in the liver, and interacting with the intestinal microflora. The natural compounds discussed in these papers target a variety of pathways, such as the AMPK pathway and the TGF-β pathway, and have significant therapeutic effects. This review aims to provide new possible therapeutic lead compounds and references for the development of novel medications and the clinical treatment of NAFLD. It offers fresh perspectives on the development of natural compounds in preventing and treating NAFLD.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>37570615</pmid><doi>10.3390/molecules28155645</doi><orcidid>https://orcid.org/0000-0001-7621-0715</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1420-3049
ispartof Molecules (Basel, Switzerland), 2023-07, Vol.28 (15), p.5645
issn 1420-3049
1420-3049
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_b7a4f73c71bf4f4abe23928ca08a2b65
source Open Access: PubMed Central; Publicly Available Content Database; Coronavirus Research Database
subjects Antioxidants
Care and treatment
Cytokines
Enzymes
Fatty acids
Fatty liver
Flavonoids
Health aspects
hepatic steatosis
Homeostasis
Humans
Inflammation
Inflammation - metabolism
Insulin Resistance
Lipids
Liver
Liver diseases
Metabolism
Metabolites
Microbiota
Microbiota (Symbiotic organisms)
natural compounds
non-alcoholic fatty liver disease
Non-alcoholic Fatty Liver Disease - metabolism
Oxidation
Oxidative Stress
Pathogenesis
Proteins
Review
Sterols
Transcription factors
Transforming growth factors
Tumor necrosis factor-TNF
Type 2 diabetes
title Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A55%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20Mechanism%20Pathways%20of%20Natural%20Compounds%20for%20the%20Treatment%20of%20Non-Alcoholic%20Fatty%20Liver%20Disease&rft.jtitle=Molecules%20(Basel,%20Switzerland)&rft.au=Fang,%20Xiaolei&rft.date=2023-07-25&rft.volume=28&rft.issue=15&rft.spage=5645&rft.pages=5645-&rft.issn=1420-3049&rft.eissn=1420-3049&rft_id=info:doi/10.3390/molecules28155645&rft_dat=%3Cgale_doaj_%3EA760516853%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c561t-6c1cbbb61004e2880754528984752c8666ddeb5f4a35f77a23e2699a319689003%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2849061419&rft_id=info:pmid/37570615&rft_galeid=A760516853&rfr_iscdi=true